» Articles » PMID: 37974706

Use of Temporalis Muscle and Temporoparietal Fasciocutaneous Flap (TPPF) for Orbital Exentration Defects: Our Experience of 10 Cases

Overview
Publisher Springer
Date 2023 Nov 17
PMID 37974706
Authors
Affiliations
Soon will be listed here.
Abstract

Orbital defects represent difficulties in head and neck reconstruction owing to 3-dimensional complexity of the socket with aim to restore form and function. Recommended methods of reconstruction include mucosal and skin grafts free microvascular myofascial or fasciocutaneous flaps. However, most frequently, reconstruction of orbital defects calls for measures somewhere in between. The temporoparietal fascia flap (TPFF) fits well as it provides thin, pliable coverage of defects with dependable blood supply, tolerance for a large degree of rotation and minimal donor site morbidity. We hereby present our experience and results of 10 cases using TPPF and temporalis muscle post orbital exentration defects.Ten patients (7 male and 3 females) age ranging from 25 to 64 years underwent reconstruction of orbital exenteration defects using TPPF and temporalis muscle from June 2019 to June 2020 in our department. The primary disease was squamous cell carcinoma (SCC) of orbital structures (anterior compartment) in all 10 patients. All cases were clinically N0 and M0.All patients had successful transfer of TPFF grafts and temporalis muscle transfer without flap compromise. TPPF was used in all 10 patients while Temporalis muscle flap was used to fill orbital socket in our 9 patients. Temporoparietal fascial flap showed viable option for subtle orbital and malar contour defect. All patients had intact dura with residual orbital cavity after resection reconstructed with TPPF and temporalis muscle without any additional flap usage. No frontal paralysis or orbital fistula was seen but local recurrence occurred in one patient in follow up and managed with RT. The TPFF is one of the most reliable and versatile regional flaps in the head and neck for orbital reconstruction.

References
1.
Ben Simon G, Schwarcz R, Douglas R, Fiaschetti D, McCann J, Goldberg R . Orbital exenteration: one size does not fit all. Am J Ophthalmol. 2005; 139(1):11-7. DOI: 10.1016/j.ajo.2004.07.041. View

2.
Cook Jr B, Bartley G . Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001; 108(11):2088-98; quiz 2099-100, 2121. DOI: 10.1016/s0161-6420(01)00796-5. View

3.
Rose G, Wright J . Exenteration for benign orbital disease. Br J Ophthalmol. 1994; 78(1):14-8. PMC: 504683. DOI: 10.1136/bjo.78.1.14. View

4.
Rahman I, Cook A, Leatherbarrow B . Orbital exenteration: a 13 year Manchester experience. Br J Ophthalmol. 2005; 89(10):1335-40. PMC: 1772872. DOI: 10.1136/bjo.2004.062471. View

5.
Roche P, Timon C . Orbital exenteration in periorbital malignancies. Surgeon. 2012; 10(4):189-93. DOI: 10.1016/j.surge.2011.03.006. View